Cannara Biotech Inc. has seen a notable increase in its stock price this week, alongside some significant developments in the cannabis sector.
Cannara Biotech Inc. (LOVE.TO) has had a positive week, with its stock price rising by 5.56% over the past week and a daily increase of 6.15% on Wednesday. This rise comes amid strategic advancements and upcoming financial disclosures.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$187.69M
P/E
17.3x
52W high
$2.05
52W low
$1.55
1W change
+1.60%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 76.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+76.7% Upside
Current Price
C$1.91
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
40.3%
Annualized
90-Day Vol
36.1%
Annualized
Trend (90d)
+34.4%
Annualized drift
90d Mean
C$2.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.99 | C$1.73 – C$2.29 |
| 60 trading days | C$2.07 | C$1.70 – C$2.52 |
| 90 trading days | C$2.16 | C$1.70 – C$2.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note Cannara's recent price action and its strategic moves in the cannabis sector, while also considering the lack of immediate news catalysts this week.
Cannara's stock has surged by 6.15% today, closing at C$1.88.
With a beta of 0.35, Cannara's stock is less volatile than the market, which may appeal to risk-averse investors.
Bull case
The company is performing well, showing a solid profit margin of 9.0% and a return on equity of 9.5%. Analysts are optimistic, with an average target of C$3.19, indicating significant upside potential.
Bear case
Despite its recent gains, Cannara operates in a competitive cannabis market. Any delays or challenges in its strategic initiatives could pose risks to its growth.
Recent Price Action
Advertisement
Cannara Biotech Inc. closed at C$1.88, marking a 6.15% increase for the day and a 5.56% rise over the past week. The stock has also seen a monthly increase of 11.76% and a year-to-date performance of 3.26%. This positive momentum reflects growing investor interest, likely linked to its strategic initiatives and market positioning.
Company Developments
While there haven't been significant announcements this week, Cannara has been active recently. Notably, the company secured exclusive Canadian rights to Blue River’s Ampersand™ Live Rosin Infusion Technology on July 2, 2026. Additionally, it completed the acquisition of Medican Organic Inc. in May, enhancing its operational capacity and market presence. Investors should watch for the upcoming fiscal Q3 2026 financial results announcement scheduled for July 15, 2026.
Technical Picture
The technical indicators for Cannara Biotech suggest a generally positive outlook. The stock is currently trading above its 50-day moving average of C$1.71 and its 200-day moving average of C$1.76, both positive signs of momentum. The stock has a 52-week trading range of C$1.55 to C$2.05, placing it at 66% of its range. With a beta of 0.35, Cannara's stock shows lower volatility compared to the broader market, making it potentially appealing for conservative investors. The latest trading volume of 79,990 shares is significantly higher than the 20-day average of 42,526 shares, indicating increased trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
